Has the ability to give informed consent, or for cognitively or decisionally impaired individuals (vulnerable population), the availability of a family member or guardian to give consent and assist in the consent process
INR > 1.5 or other evidence of impaired hepatic synthesis function.
Decision impaired patients
History of impaired adrenal gland function (eg, Addison's disease, Cushing's syndrome).
Impaired renal function
Medical condition that would contraindicate allogeneic transplantation as per standard practice guidelines (e.g., impaired cardiopulmonary function, hepatitis, etc)
Patients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)
Impaired heart function
Patients who are cognitively impaired and unable to consent for the study
Impaired liver or bone marrow function
Bone marrow impairment, renal impairment, liver function abnormality and impaired cardiac function as defined in the protocol
Impaired liver or bone marrow function
Impaired pulmonary function
No patients being decisionally impaired
Decisionally impaired patients
Cognitively impaired patients who cannot provide informed consent
History of any disease that could lead to impaired absorption of drugs
History of impaired adrenal gland function
substantially impaired gastrointestinal function
History of any disease that could lead to impaired absorption of drugs
Patients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)
Impaired heart function
For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be tested within 7 days of starting the study treatment:
For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of starting the study treatment:
For subjects with SEVERELY IMPAIRED renal function:
Impaired oxygenation
Exclusion of people that do not understand the risks, such as decisionally-impaired individuals, prisoners, and vulnerable populations
Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.
Impaired heart function
Patients who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible.
Known or judged to be cognitively impaired (e.g., dementia, retardation, psychosis)
Vulnerable populations: cognitively impaired; prisoners; terminally ill; elderly and infirm; drug addicts
Recent injury which may result in impaired mobility
Impaired gastrointestinal absorption
No patients being decisionally impaired
Decisionally impaired patients
Has medical or health issues prohibiting computer use (e.g., vision-impaired, cognitively impaired, illness or accident impairing computer function)
Subject has an acute psychiatric disorder or is cognitively impaired
Patients with impaired renal function (eGFR < 30)
Mentally/physically impaired/unresponsive
No evidence of impaired hepatic or kidney function
Patient with known severely impaired renal function (defined as eGFR MDRD< 30 ml/min/1.73m2)
Subject has had either a) previous axilla surgery, b) reduction mammoplasty, or c) lymphatic function that is impaired in the surgeon's judgment.
Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
Vulnerable Populations\r\n* The following groups will be excluded from participation:\r\n** Children\r\n** Decisionally impaired adults\r\n** Prisoners\r\n** Pregnant women
Decisionally impaired patients
Individuals who are cognitively impaired
Impaired renal function defined as eGFR< 50 mL/min/1.73m2
